NR3C1 and neoplasm: Both GR and AR have similar structures and mechanisms of action; thus, in mCRPC, whenever a treatment is used to block AR signaling[93], GR is usually activated to attach to nuclear AREs and activate genes that stimulate tumor progression and cell endurance[94].